RASolute 302: lessons learned and the road ahead in pancreatic cancer
Andrew H Ko · 2026
Read RASolute 302: lessons learned and the road ahead in pancreatic cancer by Andrew H Ko (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13628383.txt.
Description
Oncologist Andrew Ko reviews a landmark trial result in pancreatic cancer, in this 2026 article. Pancreatic cancer that has spread is among the hardest cancers to treat, and new drugs usually add only small gains. The RASolute 302 trial tested a drug called daraxonrasib, which blocks the RAS signals that drive most of these tumors, in patients whose first treatment had failed. It was compared with standard second-line chemotherapy.
Patients on the new drug lived markedly longer, with the risk of death cut by more than half, and average survival beyond thirteen months. Tumor shrinkage, time without growth, and quality of life all favored the drug too. Its typical side effects were rash, mouth soreness, and diarrhea, sometimes forcing dose breaks. Ko discusses what the result teaches and what comes next, including who should get the drug and how it may move into earlier treatment.
Catalog record
| CREATOR | Andrew H Ko |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 10 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |